TCMD · Tactile Systems Technology Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.7M | first quarter of 2026 | — |
|
|
|||
| Medicare channel sales growth | 40% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCMD
this stock
Tactile Systems Technology Inc
|
$641.27M | -2.0% | +12.5% | 32.7 | 10.8% |
|
ABT
Abbott Laboratories
|
$175.59B | -20.0% | +5.7% | 28.2 | 1.3% |
|
SYK
Stryker Corp
|
$119.38B | -10.3% | +11.2% | 36.0 | 1.8% |
|
MDT
Medtronic plc
|
$105.35B | -13.6% | +8.4% | 22.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$63.65B | -54.7% | +5.5% | 17.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCMD | +2.9% | +8.4% | -2.3% | -4.5% | -2.0% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | +3.4% | +7.9% | -9.9% | -4.7% | -11.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.